Other
Fair Value Measurement Disclosure
Amgen Fair Value Measurement Disclosure decreased by 4.2% to $792M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.0%, from $880M to $792M. Over 2 years (FY 2023 to FY 2025), Fair Value Measurement Disclosure shows a downward trend with a -13.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2015
Last reportedQ1 2026Apr 30, 2026
Metric ID:
fair_value_measurement_disclosureHistorical Data
10 periods
| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.09B | $1.07B | $1.03B | $886M | $1.02B | $880M | $1.02B | $904M | $827M | $792M |
| QoQ Change | — | -1.8% | -4.2% | -13.7% | +15.3% | -13.9% | +15.8% | -11.3% | -8.5% | -4.2% |
| YoY Change | — | — | — | — | -6.4% | -17.9% | -0.8% | +2.0% | -19.1% | -10.0% |
Range$792M – $1.09B
CAGR-13.3%
Avg YoY Growth-8.7%
Median YoY Growth-8.2%
Current Streak3 quarters decline
Fair Value Measurement Disclosure at Other Companies
Frequently Asked Questions
- What is Amgen's fair value measurement disclosure?
- Amgen (AMGN) reported fair value measurement disclosure of $792M in Q1 2026.
- How has Amgen's fair value measurement disclosure changed year-over-year?
- Amgen's fair value measurement disclosure decreased by 10.0% year-over-year, from $880M to $792M.
- What is the long-term trend for Amgen's fair value measurement disclosure?
- Over 2 years (2023 to 2025), Amgen's fair value measurement disclosure has grown at a -13.0% compound annual growth rate (CAGR), from $1.09B to $827M.